Sign in to fuzzto save your conversations, follow your research and come back anytime.
Symbiotec Pharmalab
SYMBIOTEC
NSE
BSE
NSEBSE1,067.45
Loading chart…
NSEBSECompany insights, generated from the most recent coverage.
96% revenue concentration in APIs exposes business to regulatory scrutiny and global price volatility.
Listed flat (0% gain) on NSE despite 71x subscription — rich IPO valuation (P/E ~56x) and large OFS component (91%) capped upside.
Retail subscription weak at 13x vs QIB at 172x — lack of retail enthusiasm limited listing momentum despite institutional demand.
